KIMMTRAK Q3 Sales Slip to $102.2M as Net Loss Widens to $14.2M
IMCR is trading near its 52-week low of $27.5 (3.3% above the low).
Summary
Q3 KIMMTRAK net sales fell to $102.2 million from $103.7 million a year earlier, which the company attributes to US wholesaler stocking pulled into Q2 and one fewer selling week in the US in Q3 2025; normalizing for both, underlying growth was about 10%. The quarter swung to a $14.2 million net loss ($0.28 per share) from roughly breakeven a year ago, with R&D up to $74.7 million on three Phase 3 programs. Nine-month sales of $324.8 million are up 10% year over year, and cash stands at $901.3 million, though about $120 million of sales-related rebate accruals are payable in Q4. The key pipeline readout, TEBE-AM topline overall survival in previously treated cutaneous melanoma, is now guided to Q2 2027, pushing the main value driver further out. Also new: the first type 1 diabetes patient dosed in the Phase 1 IMC-S118AI trial and a planned randomized Phase 2/3 DUET-UVEAL study of KIMMTRAK plus brenetafusp.
At the time of this announcement, IMCR was trading at $28.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $27.50 to $40.71. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.